[Form 4] ICU MEDICAL INC/DE Insider Trading Activity
ICU Medical Inc.'s President, Daniel Woolson, reported an open-market sale of 2,123 shares of common stock at a weighted average price of $132.2114 per share, totaling approximately $280,685. Following this transaction, Woolson directly holds 22,479 shares. The Form 4 filing indicates the sale occurred on May 22, 2026, with trade prices ranging from $132.03 to $132.33.
A Look At ICU Medical (ICUI) Valuation After Strong Q1 2026 Earnings Beat
ICU Medical (ICUI) beat Wall Street expectations for Q1 2026 earnings, leading to a short-term share price bounce. Despite a 26% discount to its estimated intrinsic value and 35% below analyst targets, the stock's valuation is complex due to a high P/E ratio compared to industry averages and potential risks from tariffs and regulatory scrutiny. The article suggests investors should conduct further analysis to weigh the risks and rewards.
ICU Medical's Valuation Upgrade Signals Strong Financial Health and Market Potential
ICU Medical, Inc. has received a significant valuation upgrade, moving from "fair" to "very attractive," based on its strong financial metrics. Key indicators such as a P/E ratio of 47, an EV to EBITDA ratio of 13.11, and a low PEG ratio of 0.23 suggest a solid operational efficiency and potential undervaluation relative to growth. The company also demonstrates strong fundamentals with a robust EBIT to interest ratio of 16.14 and reported a net profit of USD 14.46 million for the quarter ending December 2025.
Is ICU Medical’s Profit Rebound Despite Lower Sales Altering The Investment Case For ICU Medical (ICUI)?
ICU Medical, Inc. reported a return to profitability in Q1 2026, with net income of US$30.13 million despite lower sales, indicating improved cost control. While this supports a near-term margin improvement catalyst, potential risks from tariffs and restructuring costs remain. The company's future projections include $2.4 billion revenue and $138.5 million earnings by 2029, suggesting a fair value of $180.17 per share.
ICU Medical shareholders approve charter amendments and director elections
ICU Medical shareholders approved several amendments to the company's charter at their 2026 annual meeting, including eliminating supermajority voting requirements and allowing stockholders holding at least 25% of voting power to call special meetings. They also elected directors and ratified Deloitte & Touche LLP as their independent registered public accounting firm. The company's Q1 2026 earnings surpassed analyst expectations.
Is ICU Medical’s Profit Rebound Despite Lower Sales Altering The Investment Case For ICU Medical (ICUI)?
ICU Medical, Inc. reported a return to profitability in Q1 2026 with US$30.13 million in net income, despite a decrease in sales, indicating improved cost control. This profit exceeds the lower end of their full-year GAAP net income guidance of US$26 million to US$44 million. While margin improvement is a positive, the article warns investors to consider ongoing tariff and restructuring costs that could still impact future profitability and cash generation.
ICU Medical (ICUI) reshapes voting rules, rejects 10% special meeting bid
ICU Medical (ICUI) shareholders approved significant governance changes, including adopting simple majority voting for certain provisions and granting shareholders owning at least 25% of voting power the right to call special meetings. Concurrently, a proposal to establish a 10% shareholder special meeting right was rejected. These changes, effective upon filing with the Delaware Secretary of State, also involved the election of all director nominees, ratification of Deloitte & Touche LLP as auditor, and advisory approval of executive compensation.
ICU Medical shareholders approve charter amendments and director elections
ICU Medical, Inc. (NASDAQ:ICUI) shareholders approved several significant changes to the company's charter and bylaws at their 2026 annual meeting. These amendments include eliminating supermajority voting requirements, allowing shareholders with at least 25% voting power to call special meetings, and electing all nominated directors. Additionally, Deloitte & Touche LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.
Is ICU Medical’s Profit Rebound Despite Lower Sales Altering The Investment Case For ICU Medical (ICUI)?
ICU Medical (ICUI) reported a return to profitability in Q1 2026 despite lower sales, with a net income of US$30.13 million. This indicates progress in cost control and operational efficiency. The company's full-year GAAP net income guidance ranges from US$26 million to US$44 million, with Q1 already within this range, highlighting the importance of sustained cost discipline. While a Simply Wall St Community member sees a fair value of US$180 per share, investors are cautioned about potential risks from ongoing tariffs and integration costs affecting future profitability.
ICU Medical Reports Q1 2026 Results: Revenue and EPS Top Wall Street Consensus - News and Statistics
ICU Medical reported strong first-quarter 2026 results, exceeding Wall Street expectations for both revenue and adjusted EPS. The company's performance was primarily driven by robust growth in its Infusion Systems and consumables segments, despite a decline in the Vital Care division due to strategic exits from non-core product lines. Management addressed analyst concerns regarding new hardware approvals and margin sustainability, reaffirming its full-year guidance.
5 Must-Read Analyst Questions From ICU Medical’s Q1 Earnings Call
ICU Medical's Q1 2026 results exceeded Wall Street expectations, with strong performance in Infusion Systems and consumables. CEO Vivek Jain highlighted large volume pumps as a key growth driver, while Vital Care revenues saw a decline due to strategic exits from non-core product lines. Analysts focused their questions on new hardware approvals, Infusion Systems growth, the impact of regulatory warnings, pricing strategies for new pumps, and the sustainability of margin improvements.
Thrivent Financial for Lutherans Grows Position in ICU Medical, Inc. $ICUI
Thrivent Financial for Lutherans significantly increased its stake in ICU Medical (NASDAQ:ICUI) by 1,604% in the fourth quarter of 2025, now owning over 303,000 shares valued at approximately $43.3 million. Other major institutional investors also boosted their holdings, with institutional investors now owning 96.10% of the company's stock. Despite some recent insider selling and price target adjustments, analysts maintain a "Buy" consensus with an average price target of $169.00, and the company reported better-than-expected quarterly EPS of $1.97.
ICU Medical VP Sanzone sells $303,623 of company stock By Investing.com
Virginia Sanzone, Vice President and General Counsel at ICU Medical Inc., sold 2,447 shares of company stock for a total of $303,623 at $124.08 per share. Following this transaction, Ms. Sanzone directly holds 19,460 shares. The company's stock currently trades at $120.81, down 13% year-to-date, though InvestingPro analysis suggests it is undervalued despite a high P/E ratio.
ICU Medical VP Sanzone sells $303,623 of company stock
Virginia Sanzone, VP and General Counsel at ICU Medical Inc., sold 2,447 shares of company stock for $303,623 on May 14, 2026. This transaction leaves Ms. Sanzone with 19,460 directly held shares. The company recently reported strong Q1 2026 earnings, exceeding analyst expectations for both EPS and revenue, though its stock trades at a high earnings multiple.
ICU Medical VP Sanzone sells $303,623 of company stock
Virginia Sanzone, VP and General Counsel at ICU Medical Inc. (NASDAQ:ICUI), sold 2,447 shares of company stock for $303,623 on May 14, 2026. This transaction reduced her direct holdings to 19,460 shares. The company recently reported strong Q1 2026 results, exceeding analyst expectations for both EPS and revenue.
ICU Medical (ICUI) director adds shares via 1,254-share exercise and 1,475 RSU grant
ICU Medical (ICUI) director Donald Abbey reported acquiring shares through equity compensation rather than open-market trading. On May 13, 2026, Abbey exercised derivative securities to obtain 1,254 shares of common stock and was granted 1,475 Restricted Stock Units (RSUs) which vest on the grant anniversary or next annual stockholder meeting. Following these transactions, Abbey directly holds 6,004 shares of common stock and 1,475 RSUs, with the RSUs having no purchase or exercise price.
ICUI SEC Filings - Icu Medical 10-K, 10-Q, 8-K Forms
This article provides access to SEC filings for ICU Medical (ICUI), including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. It highlights that the company's SEC filings detail operations, governance, financial disclosures, and executive compensation. A recent filing from August 8, 2025, involved adding 2.15 million shares to the 2011 Stock Incentive Plan.
ICU Medical's (NASDAQ:ICUI) Shareholders May Want To Dig Deeper Than Statutory Profit
ICU Medical (NASDAQ:ICUI) recently reported solid earnings, but an analysis reveals concerning factors for shareholders beyond the statutory profit. The company's profit was impacted by a US$26m expense due to unusual items and boosted by an unusual US$37m tax benefit. These contrasting considerations make it difficult to determine if the reported profits accurately reflect the company's true underlying potential.
5 Must-Read Analyst Questions From ICU Medical’s Q1 Earnings Call
ICU Medical (ICUI) outperformed Wall Street expectations in Q1 2026, with revenue and adjusted EPS exceeding consensus due to strong growth in Infusion Systems and consumables. The article highlights five key analyst questions from the earnings call, addressing topics such as new hardware approvals, balanced Infusion Systems growth, the impact of regulatory actions, pricing strategy for new pumps, and the sustainability of margin improvements. The company's management provided insights into these critical areas, and the article concludes by outlining catalysts for upcoming quarters.
Fuller & Thaler holds 4.94% of ICU Medical (ICUI) as of 03/31/2026
Fuller & Thaler Asset Management has reported a 4.94% beneficial ownership in ICU Medical (ICUI) as of March 31, 2026, through a Schedule 13G/A filing. This report classifies their investment as a passive position, indicating no intent to control the company. The filing details their sole voting power over 1,201,822.95 shares and sole dispositive power over 1,220,538.95 shares.
ICU medical director David Greenberg sells $297,933 in stock
David C. Greenberg, a director at ICU Medical Inc., recently sold 2,424 shares of common stock for $297,933 after acquiring them through option exercises. He also received additional shares through restricted stock unit vestings and grants, now holding 9,214 shares. This follows ICU Medical's strong Q1 2026 earnings, which surpassed market expectations.
ICU Medical (ICUI) director reports RSU vesting and new equity grant
ICU Medical director Kolleen T. Kennedy reported equity activity on May 13, 2026, including the vesting of 1,254 Restricted Stock Units (RSUs) into common shares, increasing her direct holdings to 4,539 shares. On the same date, Kennedy also received a new grant of 1,475 RSUs, which have no purchase or exercise price and will vest on the grant anniversary or the next annual stockholder meeting. This information was disclosed in a Form 4 SEC filing.
ICU medical director David Greenberg sells $297,933 in stock
David C. Greenberg, a director at ICU Medical Inc. (NASDAQ:ICUI), recently sold $297,933 worth of common stock. These transactions occurred on May 12 and 13, 2026, alongside his acquisition of shares through option exercises and restricted stock unit vestings. The company recently reported strong first-quarter 2026 earnings, surpassing market expectations with an EPS of $1.97 and revenue of $526 million.
Director at ICU Medical (ICUI) gains 1,475 RSUs and 1,254 shares
ICU Medical director David F. Hoffmeister engaged in compensation-related equity activity on May 13, 2026. He acquired 1,254 shares of Common Stock by exercising previously granted Restricted Stock Units, increasing his direct holdings to 6,004 shares. Additionally, he received a new award of 1,475 Restricted Stock Units, which will vest on the anniversary of the grant date or the next annual stockholder meeting.
[144] ICU MEDICAL INC/DE SEC Filing
This article reports on an SEC Form 144 filing by ICU MEDICAL INC/DE (ICUI). The filing details a proposed sale of 2424 common shares with an aggregate market value of $297,933.84, acquired through the exercise of options under a registered plan. The purpose of the Form 144 is to provide notice of the proposed sale of securities under Rule 144 of the Securities Act of 1933.
ICU Medical’s Margin-Fueled Earnings Beat Could Be A Game Changer For ICU Medical (ICUI)
ICU Medical (ICUI) reported a Q1 2026 earnings beat, turning a prior-year net loss into a net income of US$30.13 million, driven by higher gross margins and strong performance in core infusion systems despite a revenue decline. This performance supports the company's investment thesis in the near term, demonstrating that its core business can offset integration and restructuring costs. However, investors are advised to monitor the duration of these elevated expenses and consider multiple viewpoints before forming investment decisions.
ICU Medical’s Margin-Fueled Earnings Beat Could Be A Game Changer For ICU Medical (ICUI)
ICU Medical (ICUI) reported Q1 2026 earnings with sales of US$530.23 million, turning a prior-year net loss into a net income of US$30.13 million, or US$1.20 diluted EPS. Despite a headline revenue decline, the company achieved higher gross margins and stronger performance in core infusion systems, exceeding market expectations. This margin improvement, combined with reaffirmed 2026 earnings guidance, supports the investment thesis for ICU Medical, though ongoing integration costs and Vital Care underperformance remain key factors.
ICU Medical (ICUI) Margins Return To Breakeven Trailing Profit Challenging Bearish Narratives
ICU Medical (ICUI) has reached near breakeven in trailing twelve-month profit after a period of fluctuating quarterly earnings, with revenue around US$2.2 billion and a small net income of US$0.7 million. While bullish investors point to cost integration benefits, bears highlight slower revenue growth compared to the market and recurring quarterly losses. The company's valuation signals are mixed, with a low P/S ratio contrasting with a DCF fair value significantly below its current share price.
Implied volatility surging for ICU Medical stock options
This article from MSN discusses a surge in implied volatility for ICU Medical (ICUI) stock options. While the content body provided is empty, the headline indicates increased investor expectation of significant price movement for the stock.
ICU Medical (NASDAQ:ICUI) Exceeds Q1 CY2026 Expectations
ICU Medical (NASDAQ:ICUI) surpassed Wall Street's Q1 CY2026 revenue and EPS expectations, despite a year-on-year revenue decline of 11.6% to $530.2 million. The medical device company's non-GAAP profit reached $1.97 per share, beating consensus estimates by 12.5%. While past growth rates have been strong, recent performance shows revenue declines, and future projections indicate below-average sector growth, prompting questions about its profitability and efficiency despite the quarterly beats.
ICU Medical Inc reports results for the quarter ended March 31 - Earnings Summary
ICU Medical Inc. reported its earnings summary for the quarter ended March 31. The report was provided by Refinitiv and is a concise financial update for the company.
ICU Medical Announces First Quarter 2026 Results
ICU Medical, Inc. announced its first quarter 2026 financial results, with GAAP revenue declining 12% year-over-year but non-GAAP organic revenue increasing 1% when excluding the impact of the IV Solutions divestiture and foreign currency. GAAP net income was $30.1 million, or $1.20 per diluted share, a significant improvement from a net loss in the prior year. The company's CEO noted that the results were generally in line with expectations.
ICU Medical reiterates full-year view while targeting close to $150M free cash flow
ICU Medical reiterated its full-year 2024 guidance, anticipating adjusted EBITDA of $420 million to $450 million. The company also projects reaching nearly $150 million in free cash flow by year-end, following strong financial performance in its recent quarter. This outlook underscores confidence in its operational efficiency and market position.
ICU Medical: Q1 Earnings Snapshot
ICU Medical Inc. (ICUI) reported strong first-quarter results, with profits of $30.1 million and adjusted earnings of $1.97 per share, surpassing Wall Street expectations of $1.78 per share. The medical device maker also exceeded revenue forecasts, posting $530.2 million in revenue and $525.8 million in adjusted revenue against an anticipated $519.9 million. These figures indicate a successful quarter for the San Clemente, California-based company.
ICU Medical Q1 2026 slides: organic growth persists amid JV transition
ICU Medical (NASDAQ:ICUI) reported its Q1 2026 financial results, showing a 12% year-over-year revenue decline to $526 million due to the deconsolidation of its IV Solutions joint venture, but maintained 1% organic growth. The company exceeded earnings expectations with an adjusted EPS of $1.97 and saw strong performance in its Infusion Systems segment, while facing challenges from tariffs, logistics costs, and FDA review timelines. ICU Medical provided positive forward guidance for Q2 and Q3 2026, indicating expected sequential improvement.
ICU MEDICAL ($ICUI) Releases Q1 2026 Earnings
ICU Medical ($ICUI) released its Q1 2026 earnings, reporting $1.97 earnings per share, surpassing analyst estimates of $1.79. However, the company missed revenue estimates, bringing in $525,770,000 against an expectation of $530,892,996. The article also details recent insider trading activity, hedge fund movements, government contracts, and analyst price targets for the company.
ICU Medical: Q1 Earnings Snapshot
ICU Medical Inc. reported a Q1 profit of $30.1 million, or $1.20 per share, with adjusted earnings of $1.97 per share, surpassing analyst expectations of $1.78 per share. The medical device maker's revenue reached $530.2 million, with adjusted revenue of $525.8 million, also exceeding Street forecasts of $519.9 million. The results indicate a strong financial performance for the company in the first quarter.
Earnings Flash (ICUI) ICU Medical, Inc. Reports Q1 Revenue $530.2M, vs. FactSet Est of $520.6M
ICU Medical, Inc. (ICUI) reported its Q1 revenue at $530.2 million, surpassing FactSet's estimated revenue of $520.6 million. The company, a developer and manufacturer of medical products for infusion therapy, vascular access, and vital care, also details its product portfolio including IV pumps, catheters, and monitoring solutions. The article also provides a summary of recent news and financial ratings concerning ICU Medical.
ICU Medical (NASDAQ: ICUI) swings to Q1 2026 profit as revenue declines
ICU Medical (NASDAQ: ICUI) reported a return to profitability in Q1 2026 with a net income of $30.1 million, contrasting with a $15.5 million loss in the prior year, despite a decline in total revenue to $530.2 million. The improved net income was largely driven by a $34.7 million discrete tax benefit and reduced cost of goods sold and operating expenses. The company's revenue dip was primarily due to the 2025 sale of a majority interest in its IV Solutions business and lower Vital Care revenue, though Consumables and Infusion Systems segments saw growth.
ICU Medical (NASDAQ: ICUI) Q1 2026 revenue dips 12% but earnings improve
ICU Medical (NASDAQ: ICUI) reported a 12% year-over-year GAAP revenue decrease in Q1 2026 to $530.2 million, primarily due to the divestiture of its IV Solutions business. However, non-GAAP organic revenue, excluding the divested business and foreign currency effects, increased by 1%. The company significantly improved profitability, achieving a GAAP net income of $30.1 million compared to a net loss in the prior year, and saw its GAAP gross margin expand to 39% from 35%.
ICU Medical Announces First Quarter 2026 Results
ICU Medical, Inc. (Nasdaq:ICUI) announced its financial results for the first quarter of 2026, ending March 31, 2026. Despite a 12% GAAP revenue decline year-over-year, largely due to the divestiture of its IV Solutions business, non-GAAP organic revenue increased by 1%. The company reported GAAP net income of $30.1 million and adjusted diluted earnings per share of $1.97 for the quarter.
ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
ICU Medical (ICUI) reported Q1 earnings of $1.97 per share, surpassing the Zacks Consensus Estimate of $1.78 and outperforming last year's $1.72 earnings. The company also exceeded revenue estimates with $525.77 million against an expected $519.95 million. Despite beating estimates, ICU Medical’s stock has underperformed the S&P 500 this year, and its current Zacks Rank of #4 (Sell) suggests potential continued underperformance.
ICU Medical Swings To Profit In Q1
ICU Medical, Inc. reported a net income of $30.1 million, or $1.20 per share, in the first quarter of 2026, a significant improvement from a net loss of $15.5 million in the prior year. Adjusted earnings per share rose to $1.97. However, total revenues declined to $530.2 million due to the IV Solutions divestiture, with adjusted EBITDA slightly decreasing to $98.7 million.
ICU Medical earnings on deck: Can margins offset revenue slide?
ICU Medical Inc. is expected to report its first-quarter results soon, with analysts anticipating earnings of $1.76 per share on revenues of $522.4 million. The market will closely examine the company's ability to achieve mid-single-digit organic growth despite revenue headwinds, and whether its margin expansion strategy, including benefits from a joint venture with Otsuka and Smiths Medical synergies, can counterbalance a projected 12.9% year-over-year revenue decline. Investors will also focus on management's commentary regarding core Infusion Consumables and Systems organic growth, gross margin performance, and strategies to mitigate external cost pressures like rising oil prices and potential tariffs.
ICU Medical: Q1 Earnings Snapshot
ICU Medical Inc. reported a first-quarter profit of $30.1 million, or $1.20 per share, exceeding Wall Street expectations. Adjusted earnings were $1.97 per share, surpassing the average analyst estimate of $1.78 per share. The medical device maker also reported revenue of $530.2 million, with adjusted revenue of $525.8 million, beating Street forecasts.
ICU Medical Announces First Quarter 2026 Results
ICU Medical, Inc. announced its financial results for the first quarter ended March 31, 2026. Despite a 12% GAAP revenue decline due to the divestiture of its IV Solutions business, non-GAAP organic revenue increased by 1%. The company reported GAAP net income of $30.1 million, or $1.20 per diluted share, a significant improvement from a net loss in the prior year.
ICU Medical earnings on deck: Can margins offset revenue slide?
ICU Medical is set to report first-quarter earnings, with analysts focused on whether its margin expansion strategy can counteract a projected revenue decline. Despite a muted near-term outlook and expected decrease in year-over-year revenue, analysts remain bullish on the stock. Key areas of investor focus include organic growth commentary, gross margin performance, and the company's ability to navigate external cost pressures.
ICU Medical (ICUI) Q1 2026 Preview: EPS Est. $1.75, Reports May 7
ICU Medical (ICUI) is expected to report first-quarter 2026 earnings on May 7, with analysts predicting modest EPS growth of $1.75 per share, representing a 1.7% increase year-over-year. However, revenue is forecasted to decline by 11.4% to $531.1M, indicating a significant top-line headwind. Investors will be closely watching management's explanation for the revenue decline and the sustainability of the company's profitability in the face of these challenges.
ICU Medical (ICUI) Q1 2026 Preview: EPS Est. $1.75, Reports May 7
ICU Medical (ICUI) is projected to report first-quarter 2026 earnings of $1.75 per share, representing a 1.7% year-over-year growth, on May 7. This earnings growth is expected despite a significant 11.4% decline in revenue to $531.1 million, leading analysts to express caution through lowered estimates. Investors will be focused on management's explanation for the revenue downturn and the company's strategies to maintain profitability.
ICU Medical, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics
ICU Medical, Inc. has recently undergone a valuation adjustment, with a P/E ratio of 47 and EV to EBITDA of 13.11. The company's financial metrics, including a Price to Book Value of 1.48 and ROCE of 3.54%, are being assessed against a backdrop of mixed peer valuations in the Pharmaceuticals & Biotechnology sector. This adjustment reflects ongoing market dynamics and the company's positioning within a competitive industry.
